Heart rate variability during and after  chemotherapy with anthracycline in  patients with breast cancer

Stachowiak, Paweł; Milchert‐Leszczyńska, Marta; Falco, Michał; Wojtarowicz, Andrzej; Kaliszczak, Robert; Safranow, Krzysztof; Kornacewicz-Jach, Zdzisława

doi:10.5603/kp.2018.0098

Cited by 12 publications

(15 citation statements)

References 8 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, we found that QTc interval prolonged and RHR significantly accelerated after chemotherapy (76.20 ± 10.89 versus 80.32 ± 10.76, p < .05). Stachowiak et al (2018) also found that RHR increased in breast cancer patients using anthracyclines.…”

Section: Discussionmentioning

confidence: 83%

See 1 more Smart Citation

Cardiovascular status of breast cancer patients before and after receiving anthracycline chemotherapy regimen

et al. 2021

View full text Add to dashboard Cite

Aim To explore the effect of TEC chemotherapy regimen (Docetaxel + Epirubicin + Cyclophosphamide) on traditional cardiovascular risk factors, atherosclerotic cardiovascular disease and cardiac electrical activity. Design 243 patients with first initially diagnosed breast cancer were collected who receiving TEC chemotherapy. Methods Univariate analysis, multivariate analysis, binary logistic regression analysis and statistical description were used to analyse the data. Results Among the first diagnosed patients, prevalence of hypertension and overweight/obesity in postmenopausal patients were significantly higher than premenopausal group. Compared with initially diagnosed state, incidence of hyperlipidaemia increased significantly after TEC chemotherapy, blood glucose level was remarkably increased, and prevalence of hyperuricaemia was significantly increased, changes of blood pressure level and prevalence rate of hypertension were not significant, and there was no statistical difference. Different menopause status showed the same trend. Atherosclerotic cardiovascular disease risk stratification showed after chemotherapy low‐risk patients decrease, medium‐risk and high‐risk people increased. Grouped by menstrual status, after chemotherapy, both groups showed the same trend. The independent influencing factors of increased heart rate after chemotherapy were postmenopausal status. Postmenopausal patients had more cardiovascular risk factors than premenopausal patients. After receiving chemotherapy, levels of cardiovascular risk factors in both groups mostly changed to the direction of disease. Chemotherapy drugs increase the risk of atherosclerotic cardiovascular disease in breast cancer patients. It is necessary to strengthen interdisciplinary cooperation to dynamic assess the cardiovascular health of patients of breast cancer patients.

show abstract

Section: Discussionmentioning

confidence: 83%

“…Stachowiak et al. (2018) also found that RHR increased in breast cancer patients using anthracyclines. In our research, we also found that menopausal status may be major risk factors for increased RHR.…”

Section: Discussionmentioning

confidence: 92%

Cardiovascular status of breast cancer patients before and after receiving anthracycline chemotherapy regimen

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The autonomic balance can be evaluated by the analysis of heart rate variability (10). Stachowiak Pet al (11) detected early heart rate variability changes during chemotherapy, assessed with 24-hour Holter ECG in breast cancer patients. 24-hour Holter ECG and echocardiography examination were performed at baseline, 24 h after the first cycle of drug administration, and 24 h after the last cycle of chemotherapy.…”

Section: Results Demographic and Echocardiographic Characteristicsmentioning

confidence: 99%

Assessment of Heart Rate Variability in Children with Cancer after Elevated Cumulative Anthracycline Dose: A Prospective Study

Köker¹,

Demirağ²,

Meşe³

et al. 2021

Turkish Journal of Pediatric Disease

View full text Add to dashboard Cite

Objective: Anthracyclines which are the main drug of chemotherapy protocols had cardiotoxicity as the most frequent and well-known side effect. We aimed to evaluate prospectively the heart rate variability with 24-hour Holter electrocardiography (ECG) in children with cancer who treated with anthracycline drugs. Material and Methods:The 24-hour Holter ECG monitoring was performed at the baseline, at time of 120 mg/m 2 and ≥240 mg/m 2 of cumulative anthracycline dose in patients with cancer who treated with anthracycline. The time-domain and frequency-domain measurements of heart rate variability (HRV) were obtained. The patients were classified into three groups as Group1:at baseline(n=54), Group 2:≥120mg/m 2 (n=54), Group 3:≥240mg/m 2 (n=54). Results:The median age was 48 months (range 9-192 months). All types of cancer were 38 patients (70.4%) of acute leukemia, two patients (3.8%) of T lymphoblastic lymphoma, and 14patients (25.8%) of other childhood cancer who treated with anthracycline. However, all heart rate variability parameters were decreased after each increased cumulative anthracycline dose, especially time-domain parameters such as nSDNN index, rMSSD, pNN50, frequency parameters such as LF, HF, and Total power were significantly altered among Group1 and Group 3. LF/HF ratio was also statistically significantly increased in Group 3. According the heart rate parameters, the mean average heart rate, mean minimum heart rate and mean RR were statistically significantly prolonged from Group1 to Group 3. Conclusion:Heart rate variability parameters are a noninvasive technique to demonstrate cardiac autonomic neural dysfunction and early myocardial injury. The 24-hour Holter ECG may be used for detecting early cardiac dysautonomia effect during anthracycline treatment with each elevated 120mg/m 2 anthracycline of cumulative dose.

show abstract

“…Por su parte, estudios anteriores han reportado disfunción autonómica en el período posoperatorio tar-dío del cáncer de mama (Caro-Morán, et al 2016) y baja variabilidad de la frecuencia cardíaca durante la quimioterapia (Stachowiak, et al 2018) mediante la evaluación del control autonómico. También se ha demostrado que las mujeres supervivientes de cáncer de mama tienen menos tolerancia al ejercicio en comparación con controles sin antecedentes de cáncer (Beaudry, et al 2019;Burnett, et al 2013;Dolan, et al 2016) evaluado a través del VO 2 máx, el cual es el ritmo más alto, o límite máximo, para incrementar el consumo de oxígeno alcanzable en un ejercicio agotador o máximo (Wilmore, & Costill, 2004).…”

unclassified

Método indirecto para estimar el consumo máximo de oxígeno en supervivientes de cáncer de mama y controles sanos (Indirect method for estimating maximum oxygen consumption in breast cancer survivors and healthy controls)

Ribeiro

Benavides

González

et al. 2021

Retos

View full text Add to dashboard Cite

El objetivo de este estudio fue comparar la predicción del V̇O2máx. entre mujeres sobrevivientes de cáncer de mama y un grupo control (GC) de mujeres sin antecedentes de cáncer. Estudio de caso-control en que diecisiete mujeres en el grupo sobrevivientes de cáncer de mama (49.4 ± 8.9 años, índice de masa corporal [IMC] de 27.8 ± 2.7 kg·m-2) y 17 en el GC (47.9 ± 7.4 años, IMC de 26.2 ± 4.4 kg·m-2) fueron evaluadas. La prueba de caminata de seis minutos (PC6M) se evaluó con monitor de frecuencia cardíaca, tensiómetro digital, oxímetro de pulso y escala de Borg. El V̇O2máx. se estimó con ecuación que consideró la distancia recorrida, el peso corporal y la edad. El grupo de sobrevivientes caminó 34.8 metros más que el GC (p = .15; d = .51). También mostró una tendencia (p = .05), con un tamaño del efecto moderado (d = .76), hacia un aumento del V̇O2máx. (1.74 ± .26 L·min-1) comparado con el GC (1.56 ± .21 L·min-1). No hubo diferencias entre los grupos para las variables de frecuencia cardíaca, presión arterial y esfuerzo percibido durante la prueba (p > .05). Las participantes que recorrieron más distancia tuvieron más probabilidades de un mayor V̇O2máx. (odds ratio = 12.7; p = .002). Existieron diferencias en el V̇O2máx. entre los dos grupos, esta aptitud física debería considerarse para el tratamiento y control post-operatorio. Abstract. The aim of the study was to compare the prediction of the V̇O2max in breast cancer survivors and a control group (CG) of women without a history of cancer. It is a case-control study. Seventeen women in the breast cancer survivors (49.4 ± 8.9 years, body mass index [BMI] of 27.8 ± 2.7 kg·m-2) and 17 in the CG (47.9 ± 7.4 years, BMI of 26.2 ± 4.4 kg·m-2) were evaluated. The six-minute walk test (SMWT) was evaluated with a heart rate monitor, digital blood pressure monitor, pulse oximeter and the Borg scale. The V̇O2max it was estimated with an equation that considered the distance traveled, body weight and age. The survivors group walked 34.8 meters more than the CG (p = .15). In addition, group showed a trend (p = .05), with a moderate effect size (d = .76), towards an increase in V̇O2max (1.74 ± .26 L·min-1) compared to the CG (1.56 ± .21 L·min-1). There were no differences between the groups for the variables of heart rate, blood pressure and perceived exertion during the test (p > .05). The participants who covered the longest distance had a better chance of a V̇O2max higher (odds ratio = 12.7; p = .002). There were differences in the V̇O2max between groups, this physical fitness should be considered for post-operated treatment and monitoring.

show abstract

Heart rate variability during and after chemotherapy with anthracycline in patients with breast cancer

Cited by 12 publications

References 8 publications

Cardiovascular status of breast cancer patients before and after receiving anthracycline chemotherapy regimen

Cardiovascular status of breast cancer patients before and after receiving anthracycline chemotherapy regimen

Assessment of Heart Rate Variability in Children with Cancer after Elevated Cumulative Anthracycline Dose: A Prospective Study

Método indirecto para estimar el consumo máximo de oxígeno en supervivientes de cáncer de mama y controles sanos (Indirect method for estimating maximum oxygen consumption in breast cancer survivors and healthy controls)

Contact Info

Product

Resources

About